Jansen LM et al. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum

Dis. 2001;60(10):924–927.

Wild N et al. Diagnosis of rheumatoid arthritis: multivariate analysis of biomarkers. Biomarkers. 2008;13(1):88–

105.

Rantapää-Dahlqvist S et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the

development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741–2749.

Sun J et al. Diagnostic accuracy of combined tests of anti cyclic citrullinated peptide antibody and rheumatoid

factor for rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol. 2014;32(1):11–21.

Turesson C et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors

over 46 years. Ann Rheum Dis. 2003;62(8):722–727.

Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J

Rheumatol. 2004;33(2):65–72.

Gerli R et al. Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related

cardiovascular risk factors. Ann N Y Acad Sci. 2007;1108:372–381.

Peters MJ et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with

rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–331.

Smolen JS et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and

biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.

Singh JA et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of

disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis

Care Res (Hoboken). 2012;64(5):625–639.

Singh JA et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Arthritis Rheumatol. 2016;68(1):1–26.

Vliet Vlieland TP. Non-drug care for RA—is the era of evidence-based practice approaching? Rheumatology

(Oxford). 2007;46(9):1397–1404.

Häkkinen A et al. A randomized two-year study of the effects of dynamic strength training on muscle strength,

disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis. Arthritis Rheum.

2001;44(3):515–522.

Van Den Ende CH et al. Dynamic exercise therapy for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;

(2):CD000322.

Egan M et al. Splints/orthoses in the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2003;

(1):CD004018.

Rogers MP et al. Psychological care of adults with rheumatoid arthritis. Ann Intern Med. 1982;96(3):344–348.

Dickens C et al. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis.

Psychosom Med. 2002;64(1):52–60.

Astin JA et al. Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trials.

Arthritis Rheum. 2002;47(3):291–302.

Felson DT et al. American College of Rheumatology/European League Against Rheumatism provisional definition

of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573–586.

Xeljanz (tofacitinib citrate) [package insert]. New York: Pfizer Laboratories; 2016.

O’Dell J. Treatment of rheumatoid arthritis. In: Firestein G, ed. Kelley’s Textbook of Rheumatology. 9th ed.

Philadelphia, PA: Saunders/Elsevier; 2013:1137–1160.

TheMedicalLetter.org. Drugs for rheumatoid arthritis. Treat Guidel Med Lett. 2012;10(117):37–44.

TheMedicalLetter.org. Drugs for rheumatoid arthritis. Treat Guidel Med Lett. 2009;7(81):37–46.

Jenkins JK, Hardy KJ. Biological modifier therapy for the treatment of rheumatoid arthritis. Am J Med Sci.

2002;323(4):197–205.

Moreland LW et al. T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a

combination of Vbeta3, Vbeta14, and Vbeta17 peptides. Arthritis Rheum. 1998;41(11):1919–1929.

Moreland LW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med.

1999;130(6):478–486.

Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Immunex; 2015.

Humira (adalimumab) [package insert]. North Chicago, IL: Abbott Laboratories; 2016.

Remicade (infliximab)[package insert]. Horsham, PA: Centocor; 2015.

Cimzia (certolizumab pegol) [package insert]. Smyma, GA: UCB; 2016.

Nurmohamed MT. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the

risks? Drugs. 2009;69(15):2035–2043.

Simponi (golimumab)[package insert]. Horsham, PA:Janssen Biotech; 2016.

Singh JA et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a

Cochrane overview. Can Med Assoc J. 2009;181(11):787–796.

Louie SG et al. Biological response modifiers in the management of rheumatoid arthritis. Am J Health Syst

Pharm. 2003;60(4):346–355.

Orencia (abatacept) [package insert]. Princeton, NJ: Bristol Meyer Squibb; 2015.

Kremer JM et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a

combination of abatacept and methotrexate. Arthritis Rheum. 2008;58(4):953–963.

Rituxan (rituximab) [package insert]. South San Francisco, CA: Biogen Idec and Amgen; 2016.

Genovese MC et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a

cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013;40(6):768–780.

van Vollenhoven RF et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J

Rheumatol. 2010;37(3):558–567.

Actemra (tocilizumab) [package insert]. South San Francisco, CA: Genentech; 2014.

Lipsky PE. Interleukin-6 and rheumatic diseases. Arthritis Res Ther. 2006;8(Suppl 2):S4.

Nakahara H, Nishimoto N. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases. Endocr Metab

Immune Disord Drug Targets. 2006;6(4):373–381.

Singh JA et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic

review and meta-analysis. Lancet. 2015;386(9990):258–265.

Gorter SL et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic

literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann

Rheum Dis. 2010;69(6):1010–1014.

Kirwan JR et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database

Syst Rev. 2007(1):CD006356.

Buttgereit F et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial

(CAPRA-2). Ann Rheum Dis. 2013;72(2):204–210.

Buttgereit F et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in

rheumatoid arthritis. Ann Rheum Dis. 2010;69(7):1275–1280.

Buttgereit F et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness

of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet.

2008;371(9608):205–214.

Saag KG. Resolved: Low-dose glucocorticoids are neither safe nor effective for the long-term treatment of

rheumatoid arthritis. Arthritis Rheum. 2001;45(5):468–471.

Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15(Suppl 3):S2.

Rovati GE et al. Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular

risk. Trends Pharmacol Sci. 2010;31(3):102–107.

Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition

and beyond. J Pharm Pharm Sci. 2008;11(2):81s–110s.

Ivanova IP et al. Characterization of immunogenic properties of polyclonal T cell vaccine intended for the

treatment of rheumatoid arthritis. Bull Exp Biol Med. 2007;144(4):630–634.

Ivanova I et al. Immune responses induced by T-cell vaccination in patients with rheumatoid arthritis. Hum

Vaccin Immunother. 2014;10(5):1221–1227.

Benham H et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid

arthritis patients. Sci Transl Med. 2015;7(290):290ra287.

de Jong PH et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in

combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis.

2014;73(7):1331–1339.

Dougados M et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52

week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis.

1999;58(4):220–225.

Strand V et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and

methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159(21):2542–

2550.

Hishitani Y et al. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid

arthritis. Scand J Rheumatol. 2013;42(4):253–259.

Alten R et al. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical

trial data representing more than four years of treatment. Arthritis Rheumatol. 2014;66(8):1987–1997.

100.

101.

102.

103.

104.

Horák P et al. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data

from the ATTRA registry. Clin Rheumatol. 2013;32(10):1451–1458.

Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2014;8:87–100.

Buch MH et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann

Rheum Dis. 2011;70(6):909–920.

Slimani S et al. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint

Bone Spine. 2011;78(5):484–487.

Parida JR et al. Is non-biological treatment of rheumatoid arthritis as good as biologics? World J Orthop.

2015;6(2):278–283.

Jones G et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with

moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96.

Nishimoto N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor

(SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled

trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–1167.

Burmester G et al. Tocilizumab in combination and monotherapy versus methotrexate in MTX-naive patients with

early rheumatoid arthritis. Ann Rheum Dis. 2013;72(Suppl 3):A63.

Gabay C et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis

(ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–1550.

Singh JA et al. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum.

2006;55(3):348–352.

van der Kooij SM et al. Probability of continued low disease activity in patients with recent onset rheumatoid

arthritis treated according to the disease activity score. Ann Rheum Dis. 2008;67(2):266–269.

Daul P, Grisanti J. Monitoring response to therapy in rheumatoid arthritis—perspectives from the clinic. Bull

NYU Hosp Jt Dis. 2009;67(2):236–242.

Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index

(CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(5, Suppl

39):S100–S108.

Hicks A et al. Medical imaging and radiographic analysis of the rheumatoid patient. Clin Podiatr Med Surg.

2010;27(2):209–218.

Cohen G et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis.

2007;66(3):358–363.

Koopman WJ Moreland LW. NSAIDs for RA. In: Koopman WJ, Moreland LW, eds. Arthritis and Allied

Conditions: A Textbook of Rheumatology. 15th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.

Mann JL, Evans TS. Gastrointestinal-related complications in a long-term care population taking NSAIDs versus

COX-2 inhibitor therapy. Consult Pharm. 2004;19(7):602–613.

McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the

observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633–

1644.

Bhala N et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses

of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779.

Massó González EL et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal

bleeding. Arthritis Rheum. 2010;62(6):1592–1601.

Roth SH. NSAID gastropathy. A new understanding. Arch Intern Med. 1996;156(15):1623–1628.

García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional

NSAIDs and COXIBs in the general population. Gastroenterology. 2007;132(2):498–506.

Silverstein FE et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for

osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term

Arthritis Safety Study. JAMA. 2000;284(10):1247–1255.

Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs—differences and similarities. N Engl J Med.

1991;324(24):1716–1725.

Wolfe MM et al. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med.

1999;340(24):1888–1899.

Singh G et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid

arthritis. A prospective observational cohort study. Arch Intern Med. 1996;156(14):1530–1536.

Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

126.

127.

128.

129.

130.

131.

132.

133.

1999;56:18–24.

TheMedicalLetter.org. Treatment of peptic ulcers and GERD. Treat Guidel Med Lett. 2008;6(72):55–60.

Graham DY et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a

double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch

Intern Med. 2002;162(2):169–175.

Lanza FL et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol.

2009;104(3):728–738.

Vergara M et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in

NSAID users. Aliment Pharmacol Ther. 2005;21(12):1411–1418.

Albeldawi M et al. Managing acute upper GI bleeding, preventing recurrences. Cleve Clin J Med.

2010;77(2):131–142.

Lanas A. Prevention and treatment of NSAID-induced gastroduodenal injury. Curr Treat Options Gastroenterol.

2006;9(2):147–156.

Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J

Allergy Clin Immunol. 2003;111(5):913–921; quiz 922.

Woessner KM et al. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum.

2002;46(8):2201–2206.

Martín-García C et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest.

2002;121(6):1812–1817.

Gyllfors P et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the

cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol. 2003;111(5):1116–1121.

Anderson RJ et al. Unrecognized adult salicylate intoxication. Ann Intern Med. 1976;85(6):745–748.

May N et al. Selective COX-2 inhibitors: a review of their therapeutic potential and safety in dentistry. Oral Surg

Oral Med Oral Pathol Oral Radiol Endod. 2001;92(4):399–405.

Douketis JD et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention

of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Chest. 2012;141(2, Suppl):e326S–350S.

Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Hematol Am Soc Hematol

Educ Program. 2012;2012:529–535.

Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility,

pregnancy, and lactation. Arch Intern Med. 2000;160(5):610–619.

Dunn MJ et al. Nonsteroidal anti-inflammatory drugs and renal function. J Clin Pharmacol. 1988;28(6):524–529.

Rossat J et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin

Pharmacol Ther. 1999;66(1):76–84.

Risser A et al. NSAID prescribing precautions. Am Fam Physician. 2009;80(12):1371–1378.

Chou R et al. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis. Rockville, MD: Agency

for Healthcare Research and Quality (US); 2006.

Miller MJ et al. Renal metabolism of sulindac: functional implications. J Pharmacol Exp Ther. 1984;231(2):449–

456.

Hudson M et al. Differences in outcomes of patients with congestive heart failure prescribed celecoxib,

rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ. 2005;330(7504):1370.

Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med.

1984;310(9):563–572.

Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf.

1997;17(5):277–289.

American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug

therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39(5):723–731.

Plaquenil (hydroxychloroquine) [package insert]. Laval, Quebec: Sanofi-Aventis; 2015.

TheMedicalLetter.org. Drugs for Rheumatoid Arthritis. Treat Guidel Med Lett. 2014;56(1458):6.

Micromedex Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Micromedex. Updated

periodically.

Braun J et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of

methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, doubleblind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73–81.

Visser K et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic

134.

135.

136.

137.

138.

139.

140.

141.

142.

143.

144.

145.

146.

147.

148.

149.

150.

151.

152.

153.

154.

155.

disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a

broad international panel of rheumatologists in the 3E Initiative. Ann Rhuem Dis. 2009;68(7):1086–1093.

Imokawa S et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine

patients. Eur Respir J. 2000;15(2):373–381.

Bauters T et al. Delayed elimination of methotrexate by cola beverages in a pediatric acute lymphoblastic

leukemia population. Leuk Lymphoma. 2013;54(5):3.

van Vollenhoven RF et al. Conventional combination treatment versus biological treatment in methotrexaterefractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot

trial. Lancet. 2012;379(9827):1712–1720.

Weinblatt ME et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in

patients with rheumatoid arthritis receiving methotrexate. N EnglJ Med. 1999;340(4):253–259.

Emery P et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in

active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment

trial. Lancet. 2008;372(9636):375–382.

Bathon JM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N

EnglJ Med. 2000;343(22):1586–1593.

Genovese MC et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year

radiographic and clinical outcomes. Arthritis Rheum. 2002;46(6):1443–1450.

Koike T et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with

rheumatoid arthritis. Mod Rheumatol. 2011;21(4):343–351.

Furst DE et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and

other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis. 2003;62(Suppl 2):ii2–ii9.

Weinblatt ME et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the

treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis

Rheum. 2003;48(1):35–45.

Breedveld FC et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination

therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with

early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum.

2006;54(1):26–37.

Hetland ML et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients

with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of

surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–32.

Maini R et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in

rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT

Study Group. Lancet. 1999;354(9194):1932–1939.

Mease PJ. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical

efficacy and safety. Rheumatology (Oxford). 2011;50(2):261–270.

Nesbitt A et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor

necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323–1332.

Fleischmann R et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with

rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann

Rheum Dis. 2009;68(6):805–811.

Smolen J et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the

RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68(6):797–804.

Strand V et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patientreported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1

year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther. 2009;11(6):R170.

Keystone E et al. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the

treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum

Dis. 2014;73(12):2094–2100.

McCluggage LK, Scholtz JM. Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of

rheumatoid arthritis. Ann Pharmacother. 2010;44(1):135–144.

Simponi Aria (golimumab) [package insert]. Horsham, PA:Janssen Biotech; 2016.

Emery P et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of

randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate

156.

157.

158.

159.

160.

161.

162.

163.

164.

165.

166.

167.

168.

169.

170.

171.

172.

173.

174.

175.

176.

177.

178.

therapy. Arthritis Rheum. 2011;63(5):1200–1210.

Kay J et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a

randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58(4):964–975.

Smolen JS et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis

factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase

III trial. Lancet. 2009;374(9685):210–221.

Keystone EC et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly

subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Ann Rheum Dis. 2009;68(6):789–796.

Smolen JS et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis

factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind,

placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther. 2015;17:14.

Schmitz S et al. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for

methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum

Dis. 2012;71(2):225–230.

Pavelka K et al. Comparison of survival rates of TNF alpha antagonists in rheumatoid arthritis, anklyosing

spondylitis, juvenile idiopathic arthritis and psoriatic arthritis in Czech national registry ATTRA. Ann Rheum

Dis. 2010;6(Suppl 3):525.

Neovius M et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab,

etanercept and infliximab. Ann Rheum Dis. 2015;74(2):354–360.

Kristensen LE et al. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year

observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern

Sweden. Arthritis Rheum. 2006;54(2):600–606.

Singh JA et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J.

2010;128(5):309–310.

Danila MI et al. Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr Opin Rheumatol.

2008;20(3):327–333.

Mercer LK et al. The risk of lymphoma in patients receiving anti-tumor necrosis factor therapy for rheumatoid

arthritis: results from the British Society for Rheumatology Biologics Register—rheumatoid arthritis. In: ACR

2012: Abstract 1593, Presented November 12, 2012.

Wong AK et al. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of

published randomized controlled studies. Clin Rheumatol. 2012;31(4):631–636.

FDA Drug Safety Communication: Safety Review update on reports of Hepatosplenic T-Cell Lymphoma in

adolescents and young adults receiving tumor necrosis factor (TNF) blockers, azathioprine and/or

mercaptopurine. 2011. Accessed September, 2015.

Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor

therapy: a critical review. Arthritis Res Ther. 2009;11(Suppl 1):S1.

Lloyd S et al. The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis

patients: a systematic review and meta-analysis. Rheumatology (Oxford). 2010;49(12):2313–2321.

Hyrich KL et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second antitumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort

study. Arthritis Rheum. 2007;56(1):13–20.

Genovese MC et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in

patients with an inadequate response to methotrexate. Arthritis Rheum. 2011;63(10):2854–2864.

Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford). 2011;50(3):437–449.

Westhovens R et al. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an

inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol. 2014;32(4):553–562.

Genovese MC et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N

EnglJ Med. 2005;353(11):1114–1123.

Schiff M et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who

underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the

ARRIVE trial. Ann Rheum Dis. 2009;68(11):1708–1714.

Schiff M et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis:

two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94.

Edwards JC et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl

179.

180.

181.

182.

183.

184.

185.

186.

187.

188.

189.

190.

191.

192.

193.

194.

195.

196.

197.

198.

199.

200.

J Med. 2004;350(25):2572–2581.

Cohen SB et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a

multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety

at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–2806.

Keystone E et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an

inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2009;68(2):216–221.

Emery P et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to

respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness

study. Ann Rheum Dis. 2015;74(6):979–984.

Finckh A et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus

alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum

Dis. 2010;69(2):387–393.

Navarro Coy NC, et al. The ‘Switch’ study protocol: a randomised-controlled trial of switching to an alternative

tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who

have failed an initial TNF-inhibitor drug. BMC Musculoskelet Disord. 2014;15:452.

Burmester GR et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous

tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs

in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis.

2014;73(1):69–74.

Genovese MC et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid

arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with

traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968–2980.

Emery P et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid

arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised

placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–1523.

Singh JA et al. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2011;38(1):10–

20.